Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 801.67
ACHN's Cash to Debt is ranked higher than
79% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. ACHN: 801.67 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 801.67

F-Score: 4
Z-Score: 70.58
M-Score: -4.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -46.85
ACHN's ROE (%) is ranked higher than
64% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. ACHN: -46.85 )
ACHN' s 10-Year ROE (%) Range
Min: -2537.38   Max: -38.54
Current: -46.85

-2537.38
-38.54
ROA (%) -43.66
ACHN's ROA (%) is ranked higher than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. ACHN: -43.66 )
ACHN' s 10-Year ROA (%) Range
Min: -222.21   Max: -25.33
Current: -43.66

-222.21
-25.33
ROC (Joel Greenblatt) (%) -4657.70
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. ACHN: -4657.70 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5405.56   Max: -545.99
Current: -4657.7

-5405.56
-545.99
Revenue Growth (%) -100.00
ACHN's Revenue Growth (%) is ranked higher than
52% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ACHN: -100.00 )
ACHN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -42.3
Current: -100

EBITDA Growth (%) 4.10
ACHN's EBITDA Growth (%) is ranked higher than
84% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. ACHN: 4.10 )
ACHN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 4.1
Current: 4.1

0
4.1
EPS Growth (%) 3.40
ACHN's EPS Growth (%) is ranked higher than
84% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. ACHN: 3.40 )
ACHN' s 10-Year EPS Growth (%) Range
Min: -65.5   Max: 3.4
Current: 3.4

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ACHN Guru Trades in Q3 2013

Steven Cohen 10,000 sh (-96.69%)
» More
Q4 2013

ACHN Guru Trades in Q4 2013

Chuck Royce 590,000 sh (New)
Paul Tudor Jones 48,767 sh (New)
Jean-Marie Eveillard 600,000 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

ACHN Guru Trades in Q1 2014

Steven Cohen 43,533 sh (New)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 500,000 sh (-15.25%)
» More
Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$3.08 - $4.2 $ 11.7234%0
Jean-Marie Eveillard 2013-12-31 New Buy0.01%$2.43 - $3.46 $ 11.7303%600000
John Burbank 2012-12-31 Sold Out 0.24%$7.2 - $11.1 $ 11.732%0
John Burbank 2012-09-30 New Buy0.24%$5.61 - $10.41 $ 11.766%500000
George Soros 2012-06-30 Sold Out 0.04%$5.94 - $10.95 $ 11.759%0
George Soros 2012-03-31 Reduce -50%0.09%$7.71 - $12.375 $ 11.722%250000
George Soros 2011-12-31 Add 2132.14%0.16%$4.01 - $8 $ 11.790%500000
George Soros 2011-09-30 New Buy$4.63 - $8.31 $ 11.784%22400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.20
ACHN's P/B is ranked higher than
66% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. ACHN: 9.20 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 14.22
Current: 9.2

0.79
14.22
EV-to-EBIT -17.06
ACHN's EV-to-EBIT is ranked higher than
69% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACHN: -17.06 )
ACHN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -17.06

Current Ratio 14.51
ACHN's Current Ratio is ranked higher than
93% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. ACHN: 14.51 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 14.96
Current: 14.51

1.06
14.96
Quick Ratio 14.51
ACHN's Quick Ratio is ranked higher than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. ACHN: 14.51 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 14.96
Current: 14.51

1.06
14.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.40
ACHN's Price/Net Cash is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. ACHN: 9.40 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 9.4

0.82
12.7
Price/Net Current Asset Value 9.40
ACHN's Price/Net Current Asset Value is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. ACHN: 9.40 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 12.7
Current: 9.4

0.82
12.7
Price/Tangible Book 9.10
ACHN's Price/Tangible Book is ranked higher than
72% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. ACHN: 9.10 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 9.1

0.72
77.75
Price/Median PS Value 2.30
ACHN's Price/Median PS Value is ranked higher than
62% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. ACHN: 2.30 )
ACHN' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 1.97
Current: 2.3

0.01
1.97
Forward Rate of Return (Yacktman) -12.10
ACHN's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ACHN: -12.10 )
ACHN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -12.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany
Achillion Pharmaceuticals, Inc. was incorporated in Delaware. It is a biopharmaceutical Company which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, it is currently concentrating on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. It is currently focusing its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. In addition, it has a pipeline of other product candidates for which it is currently seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of HIV infection and ACH-702 for the treatment of serious bacterial infections. The company's industry is highly competitive and subject to rapid and significant technological change. All of the drugs it is developing, if approved, would compete against existing therapies.preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. In addition, it has a pipeline of other product candidates for which it is currently seeking appropriate collaborative partners. Its strategy is to pursue patents, developed internally and licensed from third parties, and other means to otherwise protect its technology, inventions and improvements that are commercially important to the development of its business. The Company is subject to federal, state and local laws.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 

More From Our Partners
Momentum Stocks Showing Weakness Sep 15 2014 - BENZINGA

More From Other Websites
Momentum Stocks Showing Weakness Sep 15 2014
Biotech targets: Cramer's quality candidates Sep 11 2014
[video] Cramer: ACAD and ISIS have room to run Sep 11 2014
Can the Rally in Achillion (ACHN) Shares Continue? Sep 10 2014
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte Sep 05 2014
Why Achillion Pharmaceuticals (ACHN) Stock Might be a Great Pick Sep 05 2014
5 stocks to watch Sep 03 2014
Like Volatility? Trade These Four Stocks Sep 03 2014
Lightning Round: AT&T, Las Vegas Sands & more Sep 02 2014
No, the Biotech Rally Isn't Over Sep 02 2014
Morning Movers: Dollar General Ups Bid for Family Dollar; Staples Gains on Upgrade Sep 02 2014
4 Biotechs That Might Be Bought Soon Aug 29 2014
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As Aug 27 2014
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology... Aug 27 2014
Achillion Pharmaceuticals (ACHN) Surges: Stock Adds 9% in Session Aug 27 2014
Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High Aug 26 2014
US STOCKS-Wall St rises, Dow and S&P 500 set intraday records Aug 26 2014
US STOCKS-Wall St rises, Dow and S&P 500 set intraday records Aug 26 2014
3 Biotechs Surging Following InterMune Takeover Aug 26 2014
'Fast Money' Recap: Next Stop, S&P 2,100? Aug 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK